Press
Releases

Press Releases

May 16, 2022
Altimmune to Present at Upcoming Investor Conferences
GAITHERSBURG, Md. , May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022 : H.C.
January 31, 2022
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022 GAITHERSBURG, Md. , Jan. 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s
 

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe